- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: Subclavian vein.
Displaying page 1 of 1.
EudraCT Number: 2010-024597-19 | Sponsor Protocol Number: CV185-079 | Start Date*: 2011-06-21 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: Multiple-Dose Study Apixaban in Pediatric Subjects with an Indwelling Central Venous Catheter Revised Protocol 03, to incorporate Protocol amendments 1, 3 & 4 | ||||||||||||||||||
Medical condition: Prevention of VTE in pediatric subject with a central venous cathether. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) NL (Ongoing) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001975-30 | Sponsor Protocol Number: BAY59-7939/17938 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ... | |||||||||||||
Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004372-27 | Sponsor Protocol Number: 0112 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:Theravance Biopharma Ireland Limited | |||||||||||||
Full Title: A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infectiv... | |||||||||||||
Medical condition: Staphylococcus aureus Bacteremia Including Infective Endocarditis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) PL (Completed) LV (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
